Donor and recipient gastrointestinal tracts and their microbiomes are represented on the cover as converging pipes, demonstrating the interplay between the microbial communities after FMT, described in Bork et al.

Patient safety needs innovation

Advances in the applications of artificial intelligence and other technologies in health and medicine require rethinking of what patient safety means.




    Nature Medicine, in partnership with Nature Communications and Communications Medicine, is excited to announce a call for submission of innovative clinical research on the prevention, detection, diagnostic and treatment of cancer. Click here to learn how to submit your work.

  • MedInVirtualAge

    Organized by Nature Medicine, this online conference will focus on health care delivery via remote technologies — connecting individuals and health professionals, bringing care to low-resource settings, and ensuring equal access for all. October 4-6, 2022. Registration is free. Abstract submission deadline is September 8, 2022.

  • Crab, the avatar of cancer.

    Read about the latest advances in translational and clinical research, selected by the Nature Medicine editorial team.

Nature Medicine is a Transformative Journal; authors can publish using the traditional publishing route OR via immediate gold Open Access.

Our Open Access option complies with funder and institutional requirements.


  • Individuals with COVID-19 are at an increased risk for an array of neurologic disorders at 12 months, even in those who were not hospitalized during the acute phase of the infection.

    • Evan Xu
    • Yan Xie
    • Ziyad Al-Aly
    Article Open Access
  • In a study involving more than 100,000 individuals in the UK Biobank, a neural network model trained on metabolomic data can predict disease risk for over 20 conditions and adds predictive information over clinical variables for eight common diseases.

    • Thore Buergel
    • Jakob Steinfeldt
    • Ulf Landmesser
    Article Open Access
  • Analysis of outcomes of over 800 patients with relapsed/refractory diffuse large B cell lymphoma, treated with commercially available CAR T cell therapy, supports higher efficacy and also a higher toxicity of axicabtagene ciloleucel compared to tisagenlecleucel as the third or more treatment line for this type of tumor.

    • Emmanuel Bachy
    • Steven Le Gouill
    • Franck Morschhauser
    Article Open Access
  • A deep-learning algorithm that removes patient-identifying information from facial images, while retaining sufficient information for accurate disease diagnosis, has the potential to protect patient privacy and facilitate public acceptance of facial imaging for use in digital medicine.

    • Yahan Yang
    • Junfeng Lyu
    • Haotian Lin
    Article Open Access

Nature Careers